Biosimilars play a critical role in lowering drug prices. Kaiser Permanente successfully uses biosimilars to improve affordability for our members. We are eager to share best practices and work with policymakers to help facilitate a more competitive market for biologic drugs in the United States.

Our thoughts on HHS’s blueprint to lower drug prices: It’s time for a new legal and policy landscape
In May 2018, the U.S. Department of Health and Human Services (HHS) requested feedback on its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. By Murray Ross, PhD, Vice President and Institute for Health Policy Director.